What this means
This trial plans to give weight-loss drugs or metformin to 66 adults and check their biological age with a DNA test. It has not reported results yet, so it cannot tell us whether the drugs change aging.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18–75 · 66 adults with obesity
- Where
- 1 site
The science
- Registered title
- Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
- Trial ID
- NCT07293325 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Adults With Simple Obesity
- What is tested
- Semaglutide, Tirzepatide, Metformin
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Ages
- 18 Years to 75 Years
- Dates
- First posted Dec 19, 2025 · updated Dec 19, 2025
Registry summary
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.
Sites (1)
- The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China